IRB-[ADDRESS_1105670]  2018;  Amendment  8 TITLE :  A pi[INVESTIGATOR_801005] -mutated  
ameloblastoma  
[STUDY_ID_REMOVED]  
Coordinating Center  
Stanford Cancer Institute  
[ADDRESS_1105671], CA [ZIP_CODE] -5826  
 
 
[EMAIL_10891]  
Co-Investigators  
Robert West  
Professor in Pathology Pathology  
Stanford, Cali fornia [ADDRESS_1105672] -Basic Ls  
HRP (Redwood) Building  
Stanford, [LOCATION_004]  [ZIP_CODE]  
 
 Study Coordinator  
Elizabeth Winters  
 
 
Protocol Amendment 8:  [ADDRESS_1105673]  2018;  Amendment  [ADDRESS_1105674] OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................ ....................  6 
1.0 OBJECTIVES  ................................ ................................ ................................ ............................  7 
1.1 Primary Objectives  ................................ ................................ ................................ ................................ ..... 7 
1.2 Secondary Objectives  ................................ ................................ ................................ ................................  7 
2.0 BACKGROUND  ................................ ................................ ................................ ........................  7 
2.1 Study Disease  ................................ ................................ ................................ ................................ ...............  7 
2.2 Study Agents/Device/Procedur e ................................ ................................ ................................ ..........  [ADDRESS_1105675]  ................................ ................................ ................................ ...........  12 
3.2 Informed Consent Process  ................................ ................................ ................................ .....................  18 
3.3 Study Timeline  ................................ ................................ ................................ ................................ ...........  18 
4.0 TREATMENT PLAN  ................................ ................................ ................................ ..............  18 
4.1 General Concomita nt Medication and Supportive Care Guidelines  ................................ ....... 19 
4.1.1  Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]  ................................ ................................ ................  19 
4.1.2  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  ................................ ................................ ...............  20 
4.1.3  Medications to be used with Caution  ................................ ................................ ................................ .........  21 
4.2 Criteria for Removal from Study  ................................ ................................ ................................ .........  22 
5.0 STUDY AGENT INFORMATION  ................................ ................................ ........................  22 
5.1 Study  Agents:  ................................ ................................ ................................ ................................ ..............  [ADDRESS_1105676]  2018;  Amendment  8 8 CORRELATIVE/ SPECIAL STUDIES  ................................ ................................ ................  44 
8.1 Laboratory Correlative Studies  ................................ ................................ ................................ ...........  45 
8.1.1  Collection  of Specimen(s)  ................................ ................................ ................................ ...............................  45 
8.1.2  Handling of Specimens(s)  ................................ ................................ ................................ ...............................  45 
8.1.3  Shippi[INVESTIGATOR_25476](s)  ................................ ................................ ................................ ................................ . 46 
8.1.4  Site(s) Performing Correlative Study  ................................ ................................ ................................ ........  46 
8.1.5 Coding of specimens for privacy protection  ................................ ................................ ...........................  46 
9 STUDY CALENDAR  ................................ ................................ ................................ ...............  47 
10 MEASUREMENTS  ................................ ................................ ................................ ..................  49 
10.1  Primary and Secondary Outcome measures  ................................ ................................ ...................  50 
10.1.1  Measurement Definition  ................................ ................................ ................................ ................................ . 50 
10.1.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 50 
10.1.3  Measurement Time Point s ................................ ................................ ................................ .............................  50 
10.2  Secondary Outcome  ................................ ................................ ................................ ................................ . 50 
10.2.1  Tumor necrosis  ................................ ................................ ................................ ................................ ...................  50 
10.2.2  Measurement Definition  ................................ ................................ ................................ ................................ . 50 
10.2.3  Measurement Methods  ................................ ................................ ................................ ................................ .... 50 
10.2.4  Measurement Time Points  ................................ ................................ ................................ .............................  51 
10.2.5  Response Review  ................................ ................................ ................................ ................................ ...............  51 
10.3  Secondary Outcome – Proliferation index  ................................ ................................ .......................  51 
10.3.1  Measurement Definition  ................................ ................................ ................................ ................................ . 51 
10.3.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 51 
10.3.3  Measurement Time Points  ................................ ................................ ................................ .............................  51 
10.3.4  Response Review  ................................ ................................ ................................ ................................ ...............  51 
10.4  Secondary Outcome – Phosphorylation of MEK/ERK  ................................ ................................ .. 51 
10.4.1  Measurement Definition  ................................ ................................ ................................ ................................ . 52 
10.4.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 52 
10.4.3  Measurement Time Points  ................................ ................................ ................................ .............................  52 
10.4.4  Response Review  ................................ ................................ ................................ ................................ ...............  52 
11 REGULATORY CONSIDERATIONS  ................................ ................................ ..................  52 
11.1  Institutional Review of Protocol  ................................ ................................ ................................ .........  52 
11.2  Data and Safety Monitoring Plan:  ................................ ................................ ................................ ....... 52 
11.3  Data Management Plan  ................................ ................................ ................................ ...........................  53 
11.3.1  Data Collection  ................................ ................................ ................................ ................................ ....................  53 
11.3.2  Data Submission responsibility  ................................ ................................ ................................ ...................  53 
11.3.3  Multicenter Guidelines  ................................ ................................ ................................ ................................ .... 53 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ...................  53 
12.1  Statistical Design and primary analysis  ................................ ................................ ...........................  53 
12.2  Secondary Analysis  ................................ ................................ ................................ ................................ .. 54 
12.3  Sample Size  ................................ ................................ ................................ ................................ .................  54 
12.4  Accrual estimates  ................................ ................................ ................................ ................................ ..... 54 
12.5 Feasibility and safety assessment ................................ ................................ ................................ ....... 54 
13 REFERENCES  ................................ ................................ ................................ .........................  55 
Appendix A :  Medication guide for patien ts ................................ ................................ ..................  58 
Appendix B :  Stanford Cancer Institute Serious Adverse Event Reporting  ...............................  58 
Appendix C:  ECOG Performance Status  ................................ ................................ ......................  59 
Appendix D:  Cockcroft -Gault Formula ................................ ................................ .........................  60 
Appendix E:  Ophthalmic exam source sheet  ................................ ................................ ................  [ADDRESS_1105677]  2018;  Amendment  [ADDRESS_1105678] OR 
PROC EDURE  Dabrafenib  and trametinib  
PRIMARY OBJECTIVE(S)  Tumor response rate  
SECONDARY OBJECTIVE(S)  Feasibility, safety, pathological response, 
evidence of molecular pathway inhibition  
TREATMENT SUMMARY  Dabrafenib 150  mg po q 12  hours plus 
trametinib 2  mg once daily.  
SAMPLE SIZE  17 evaluable patients  
STATISTICAL CONSIDERATIONS  Simon Optimal 2 stage design  
 
IRB application number:  IRB -[ADDRESS_1105679]  2018;  Amendment  8 SCHEMA  
 
  
 
  
 
                        
   
                                             SD, PR, or CR
                    Progression or intolerable AEs
 
                                           
                        YES 
 No
                                         
        
 
                                                                 
                                                                   
                                                                                
                                                                     
                                                                                                               
                                                                                                                 
 
 Pathologically -documented ameloblastoma with BRAF -V600E or other known 
Dabrafenib -sensitive BRA F mutation in tumor by [CONTACT_342902] -certified lab  
Confirmation of eligibility and documentation of informed consent  
Baseline  biopsy, imaging, staging and clinical assessment by  
[CONTACT_801032]  / oral surgeon and medical  oncologist.  
Dabrafenib  150 mg PO q12hr plus 
Trametinib  2 mg daily PO   x 6 weeks  Response and AE assessment q3  weeks  x 2  
(see below for later assessment intervals ) 
Assessment at 6  weeks:  
Surgically resectable?  Biopsy and evaluation of 
pathological endpoints  
Resection and evaluation of pathological endpoints.  
No additional dabrafenib or trametinib  Biopsy and evaluation of 
pathological endpoints  Off-study  
Continue dabrafenib and trametinib, evaluate 
for DLT and response every [ADDRESS_1105680]  2018;  Amendment  [ADDRESS_1105681] OF ABBREV IATIONS AND DEFINITION OF TERMS  
 
ADL  Activities of daily living  
AE Adverse event  
BID Twice daily  
BSA  Body surface area  
CBC  Complete blood count  
CI Confidence interval  
CRF  Case report/Record form  
CR Complete response  
CTCAE  Common Terminology Criter ia for Adverse Events  
DLT  Dose -limiting  toxicity  
DSMB  Data Safety Monitoring Board  
ECG  Electrocardiogram  
GI Gastrointestinal  
Hgb Hemoglobin  
HTN  Hypertension  
IRB Institutional Review Board  
IV Intravenous  
LLN  Lower limit of normal  
OS Overall survi val  
PLT Platelet  
PD Progressive diseased  
PFS Progression free survival  
PR Partial response  
QD Once daily  
RECIST  Response evaluation criteria in solid tumors  
RR Response rate  
SAE  Serious adverse event  
SD Stable disease  
TTP Time to progression  
ULN Upper limit of normal  
UNK  Unknown  
WBC  White blood cell  
 
IRB-[ADDRESS_1105682]  2018;  Amendment  8 1.0 OBJECTIVE S 
1.1 Primary Objectives  
To observe the response rate of ameloblastoma to dabrafenib  plus trametinib  at 6 week s. 
1.2 Secondary Objectives  
Secondary endpoints will include feasibility and safety  in this patient population .  
Additionally, response will be assessed pathologically .  Two main histologic assays for 
treatment response will be used :  tumor necrosis and phosphorylated -MEK ;  
phosphorylated -ERK ;  and Ki -67 levels as measured by [CONTACT_34429] .   
2.0 BACKGROUND  
2.1 Study Disease  
Ameloblastoma is a rare, benign, slow -growing but locally -invasive neoplasm of 
odontogenic origin involving the mandible (80%) and maxilla with a high recurrence rate 
attributed to conservative treatment .  The neoplasm  was first described by [CONTACT_801033] 1827 . 
{Cusack, 1827 }  Etymologically, the name [CONTACT_801058] "amel" which 
means enamel and the Greek word "blastos" meaning germ or bud .  Over time, this tumor 
has been referred to by [CONTACT_801034] s includ ing “cystosarcoma,” 
“adamantine  epi[INVESTIGATOR_99186],” “adamantinoma,”  and finally “ameloblastoma.”  {Ivy, 1930 ;  
Malassez, 1885 ;  Wedl, 1870 ;  Brazis, 1995 ]  
Ameloblastoma shows variable geographic prevalence, being the most common b enign 
odontoge nic tumor in China  {Lu, 1998 ;  Wu, 198 5} and A frica {Anand, 1967 ;  
Mosadomi , 1975 ;  Barnes, 2005 }, while it is the second most common  in the United Sta tes 
and Canada {Daley, 1994 ;  Regezi, 1978 } (odontoma being most common) .  Racial bias 
has also been observed, with  African Americans at an overall five -fold increased risk of 
disease versus Caucasians . {Regezi, 1978 }  Global incidence has been estimated at 0.[ADDRESS_1105683] cases diagnosed in the age range of 30 to 60 
years . {Larsson, 1978 }  
Up to 80% of ameloblastoma cases occur in the mandible, with a particular predilection for 
the posterior mandibular region . {Reichart, 1995 }  Rare cases have been reported as 
primary to the sinonasal cavities . {Schafer, 1998 }  Often ameloblastoma can be associated 
with unerupted third molar teeth  {Stanley, 1965 ;  Gerzenshtein, 2006 ;  Becelli, 2002 } 
particularly in the unicystic type .  Desmoplastic ameloblastomas often occur in the anterior 
or premolar regions of the mandible or maxilla .  Ameloblastic carc inomas also favor the 
mandible (~2/3) over the maxilla . {Slootweg, 1984 }  Maxillary ameloblastomas also 
mostly occur in the posterior molar region.  
Histopathologically, ameloblastoma resembles normal odontogenic/enamel epi[INVESTIGATOR_801006] .  Odont ogenesis consists of chronographic and reciprocal interactions 
between the ectomesenchymal cells, which are derived from the neural crest, and the oral 
cavity lining epi[INVESTIGATOR_2130] . {Chai, 2000 }  The exact origin of ameloblastic epi[INVESTIGATOR_801007] d to arise from :  (1) cells from the rests  of enamel organ, ( 2) cells of the 
sheet of Hertwig’s or epi[INVESTIGATOR_801008], (3) epi[INVESTIGATOR_801009], particularly a dentigerous cyst, (4) basal cells of the oral mucosa, and ( 5) 
IRB-[ADDRESS_1105684]  2018;  Amendment  8 heterotrophic epi[INVESTIGATOR_801010], perhaps pi[INVESTIGATOR_2117] . {Ritchie, 1990 ;  
Bhasker, 198 1}  
Until recently, little was known about the molecular aberrations driving ameloblastoma, 
due to the tumor’s rarity and the fact that technologies to  query the tumor genome do not 
work as efficiently in formalin -fixed paraffin -embedded tissue .  However, in [ADDRESS_1105685] majority of tumors to contain 
somatic mutations impacting the mitogen -activated protein kinase (MAPK) signaling 
pathway (FGFR2 -> RAS -> BRAF) that controls cell proliferation . {Kurppa, 2014 ;  
Sweeney, 2014 ;  Brown, 2014 }  
In particular, all three studi es reported a high frequency of BRAF -V600E (valine to 
glutamic acid substitution at amino  acid 600) activating mutations at high allele frequencies 
in ameloblastomas .  In each of these reports, the BRAF -mutated neoplasms were almost 
exclusively located in the mandible .  Two of the three reports went on to characterize the 
sensitivity of BRAF -mutated ameloblastoma cells to vemurafenib, a V600E targeted small 
molecule inhibitor FDA -approved for metastatic melanoma .  Both studies showed that 
AM-1, a mandibular -derived ameloblastoma cell line harboring the BRAF -V600E 
mutation, was exquisitely sensitive to vemurafenib at concentrations similar to 
BRAF -V600E mutated melanoma and colorectal cancer cell lines .   
Surgery is the standard treatment for ameloblastomas .  Historically, the extent of resection 
has been controversial, comprising of two surgical options :  “conservative” vs.  “radical” .  
The former involves enucleation/curettage of the bony cavity, while the latter involves a 
radical operation with proper marg ins.  Advantages of enucleation include the fact that it is 
an outpatient procedure able to be performed by [CONTACT_801035] (Oral 
Surgeons and ENT), since it requires no reconstruction .  Despi[INVESTIGATOR_563943], historical data 
on simple enucl eation demonstrate recurrence rates 60  to 90% and this treatment modality 
is currently believed to play no role in the management of multicystic ameloblastomas . 
The “radical” surgical option is the current standard of care for ameloblastoma, which 
includes  enbloc resection with 1  to 2cm bone margins  {Sham, 2009 ;  Carlson, 2006 ;  
Gardner, 1980 ;  Williams, 1993 ;  Gortzak, 2006 ;  Becelli, 2011 ;  Pandya, 1972 } and 
immediate bone reconstruction to help with speech and sw allowing . {Sham, 2009 ;  
Vayvada, 2006 ;  Tsai, 2006 ;  Urken, 1991 ;  Urken, 1998 }  
The bony margin is defined as the distance away from the radiographic margin predicted to 
be disease free and oncologically safe to perform osteotomies .  Data from 82 
amelobla stoma specimens showed microscopic tumor extension 2  to 8mm (mean of 
4.5mm) beyond the radiographic boundaries of the tumor . {Carlson, 2006 }  Hence, the 
recommended bone margins are1  to 1.5cm for unicystic and 1.5  to 2cm for 
solid/multicystic histological types providing increased cure rates . {Wenig, 2007 ;  Becelli, 
2002 ;  Carlson, 2006 ;  Zwahlen, 2002 ;  Ueno, 1989 ;  Vayvada, 2006 }  Ameloblastic 
carcinoma requires 2  to 3cm bone margins with an elective neck dissection . {Ndukwe, 
2010 }  Therefore surgery for ameloblastoma, when possible, tends to be radical and 
disfiguring.  
Systemic chemotherapy has been attempted a number of times, with numerous agents and 
combinations being employed (see Table  1) {Gall, 1975 ;  Eliasson, 1989 ;  Ramadas, 1990 ;  
IRB-[ADDRESS_1105686]  2018;  Amendment  8 Grunwald, 2001 ;  Campbell, 2003 ;  Amzerin, 2011 ;  Van Dam, 2010 }.  Anecdotal  reports 
have suggested that ameloblastoma may be sen sitive to platinum based agents { Amzerin, 
2011 } although  occasional reports highlight lengthy survival without chemotherapy . 
{Ciment, 2002 ;  Hasim, 2007 }  Chemotherapy may also have a role in improvement of 
clinical symptoms in non -surgical patients . {Ciment, 2002 }  Much like radiotherapy 
though, only with continuous reporting of empi[INVESTIGATOR_801011] -based data will the role of 
systemic chemotherapy b e evaluable in this rare entity.  
Table  1:  Anecdota l reports of Chemotherapy in Ameloblastoma  
Case  Regimen  Response  Reference  
[ADDRESS_1105687] line :  5-Fluorouracil and Cisplatin ;                                    
2nd line :  Paclitaxel -Carboplatin  PR Grünwald , et al, [ADDRESS_1105688] commonly occurring adverse 
reactions in these patients treated with dabrafenib  were, in order of decreasing frequency 
hyperkeratosis, headache, pyrexia, arthralgia, papi[INVESTIGATOR_81875], alopecia, and palmar -plantar 
erythrodysesthesia syndrome (PPES) .  The most f requent adverse reactions leading to dose 
reduction of dabrafenib  were pyrexia  (9%) ;  PPES  (3%) ;  chills  (3%) ;  fatigue  (2%) ;  and 
headache  (2%).  
Dabrafenib has been demonstrated to induce response rates of 52% with a duration median 
of 5.[ADDRESS_1105689] of this 
study will be  under either an IND or FDA authorized IND  exemption .  
Trametinib is a kinase inhibitor of MEK1 and MEK2 FDA -approved for use in pat ients 
with metastatic V600E mutated melanoma based upon  a randomized control trial  (RCT ) of 
trametinib  vs chemotherapy in wh ich PFS ( 4.8 vs 1.5 mo) and RR ( 22% vs 8%) were 
IRB-[ADDRESS_1105690]  2018;  Amendment  8 higher in patients treated with trametinib . {Flaherty, 2012}   In January  [ADDRESS_1105691] which 
demonstrated an improvement in survival in the combination ( 25.1 mo median OS 
) vs dabrafenib alone (18.7  mo median OS) with corresponding response rates of 
69 vs 53% respectively . {Long, 2015}   Treatment -related adverse events occurred in 181 
(87%) of 209 patients in the dabrafenib and trametinib group and 189 (90%) of 211 patients 
in the dabrafenib only group ;  the most common was fever (108  patients, 52%) in the 
dabrafenib and trametinib group, and hyperkeratosis (70 pa tients, 33%) in the dabrafenib 
only group .  Grade 3 or 4 adverse events occurred in 67 (32%) patients in the dabrafenib 
and trametinib gro up and 66  (31%) patients in the dabrafenib only group .  Another RCT 
compared the combination of dabrafenib and trameti nib vs vemurafenib, another  TKI 
active against V600E mutant melanoma . {Robert , 2015}  In that  trial, the combination 
demonstrated improved PFS (11.4 vs 7.3 months), with similar AE and drug 
discontinuance rates.  
Therefore, it appears that in melanoma with  BRAF -V600E muta tions, t he combination is 
active and provides clinic al ben efit.  More recently, thi s combination has also been shown 
to be active in other cancers with this BRAF mutation . {Williams, 2015 ;  Brastianos, 2016 ;  
Escandel l, 2015}  Most relevant  is a report of a dramatic  response in  a patient with 
BRAF -mutant ameloblastoma . {Kaye, 2015}  Earlier this year we treated an 
ameloblastoma patient who declined major surgical resection off -label with single agent 
dabrafenib .  After [ADDRESS_1105692] the resection .  We 
observed massive amounts of tumor necrosis in the specimen, a finding very atypi[INVESTIGATOR_801012]  (report accepted for publication, Oral Surgery, Oral Medicine, 
Oral Pathology, Oral Radiology, 14 December  2015). 
2.[ADDRESS_1105693]  2018;  Amendment  8 2.4 Study Design  
This will be a single -group, single -arm, 2-stage, open non -randomized  treatment study  
whose primary endpoint is tumor  response rate wi th feasibility, safety , pathological  and 
molecular biological secondary endpoints .   
2.5 Correlative Studies Background  
Activation of the Ras/Raf/MAPK signaling pathway begins with the binding of ligands to 
receptor -linked tyrosine kinases, such as epi[INVESTIGATOR_3915] g rowth factor receptor or fibroblast 
growth factor receptor .  This leads to phosphorylation of tyrosine residues on the receptor 
that then recruits adaptor proteins (eg , GRB2 and SOS) .  This protein complex allows SOS 
to switch to an activated state that in  turn leads to activation of Ras proteins by [CONTACT_801036] .  This turns on the activity of Raf serine/threonine kinases, including B -Raf (BRAF) .  
The signaling transduction cascade then continues with the phosphorylation and activation 
of MEK1 and MEK2 tyros ine/threonine kinases .  Through phosphorylation, the MEKs 
activate the Erk MAPKs which regulate transcriptional factors that influence 
differentiation, senescence, survival, and proliferation.  
Mutations in the Ras/Raf/MAPK pathway are essential in a number  of cancers including 
the majority of melanomas with ~50% exhibiting BRAF mutations and ~ 20% exhibiting 
NRAS mutations .  In melanoma, these mutations appear at an early stage in tumorigenesis, 
including precursor lesions like benign nevi, and are preserve d through progression .  These 
are activating mutations which result in the Ras/Raf/MAPK pathway constitutively 
signaling for proliferation and survival .  Inhibition of this pathway in tumors with BRAF 
mutations turns off this pathway and shuts down essenti al survival pathways resulting in 
cell death .  BRAF inhibitor (dabrafenib ;  formerly [COMPANY_004]2118436) showed promising results 
with an approximately 2 -fold increase in progression -free survival in a phase III trial, 
which is in a simil ar range as that of  vemura fenib . {Hauschild, 2012}   
Recent studies on ameloblastoma have found BRAF -V600E mutations to be present in the 
majority of cases arising in the mandible .  Two studies have demonstrated that cell lines of 
ameloblastoma are responsive to V600E targeted small  molecule inhibitors in cell 
proliferation assays .   
Two main histologic assays for treatment response will be used :  tumor necrosis and 
phosphorylated -MEK, phosphorylated -ERK, and Ki -67 levels as measured by 
[CONTACT_9064] .  As mentioned above, sinc e the activation of the Ras/Raf/MAPK 
pathway promotes cell proliferation and survival, blockade of this pathway will result in 
cell decrease in proliferation, death and necrosis .  Furthermore, activation of the 
Ras/Raf/MAPK pathway leads to phosphorylation  of several of the pathway components, 
including MEK and ERK .  These assays for treatment response thus examine both early 
and late effects of Ras/Raf/MAPK pathway inhibition.  
Routine Hemotoxylin -Eosin stained slides from both the pre -treatment biopsy as w ell as 
definitive resection specimens will be scored for the presence of tumor necrosis, which will 
be quantified .  Additionally, unstained slides from both pre - and post - specimens from 
participating institutions will be sent to Stanford University for an alysis of 
phospho -MEK/ERK and Ki -[ADDRESS_1105694]  2018;  Amendment  [ADDRESS_1105695] be retained in the patient’s 
study file and the study’s Regulatory Binder .  
The study coordinator, treating physician and an independent reviewer must verify t hat the 
participant’s eligibility is accurate, complete, and legible in source records .  A description 
of the eligibility verification process should be included in the EPIC or other Electronic 
Medical Record progress note  or a signed version of the eligib ility checklist must be 
available in EPIC or other Electronic Medical Record for review .  
 
IRB-[ADDRESS_1105696]  2018;  Amendment  [ADDRESS_1105697] form  
I:  Trial information  
Protocol Title:  A pi[INVESTIGATOR_801013] -mutated  ameloblastoma . 
Protocol Number:  IRB-[ZIP_CODE] / ENT0043  
Principal Investigator:  A Dimitrios  Colevas  
II.  Subject Information:  
Subject Name/ID:   
Gender :     Male      Female  
III.  Study Information:  
SRC Approved  IRB Approved  Contract signed  
IV.  Inclusion/Exclusion Criteria  
Inclusion Criteria  Yes No Supporting documents  
1. Histological diagnosis of ameloblastoma .  All 
stages are eligible .  Patients must have evaluable 
disease by R ECIST criteria          
2. BRAF -V600E or other known dabrafenib 
sensitive BRA F mutation in tumor by [CONTACT_801037] -certified lab .  May include, for example, 
Sanger  sequencing, SNaPshot platform, 
immunohistochemistry , Foundation One tests, etc)         
3. At least 18  years old           
4. Life expectancy >  3 months          
5. ECOG performance status ≤ 2 (see Appendix  C)          
IRB-[ADDRESS_1105698]  2018;  Amendment  8 6. Lab values:  
 ANC  > 1.5 x 109/L 
 PLT > 99 x 109/L 
 Hemoglobin  > 8 g/dL 
 Tbili  < 1.[ADDRESS_1105699]   
o Except subjects with known Gilbert’s 
syndrome  
 AST, ALT and alk  phos < 2.6 x upper limit of 
normal  (ULN ) 
 Serum creatinine ≤ 1.5 mg/dL, or i f serum 
creatinine is > 1.5 mg/dL , creatinine 
clearance must be  50 mL/min (calculate 
creatinine clearance using the Cockcroft -Gault 
formula  (see Appendix  D).  
 PR / INR and PTT ≤ 1.[ADDRESS_1105700]  2018;  Amendment  8 2. Invasive malignancy other than ameloblastoma 
within 3 years,  excluding curatively treated basal 
cell carcinoma, and other highly curable cancers 
such as  early stage cutaneous squamous cell 
carcinoma ( T1 NO) cervical CIS, early stage 
prostate ca ncer, thyroid cancer,  breast cancer  or 
history of malignancy with confirmed activating 
RAS mutation at any time          
3. Uncontrolled hypertension  (systolic blood 
pressure >  140 mm Hg and diastolic blood 
pressure of >  90 mm Hg which cannot be 
controlled by [CONTACT_14181] -hypertensive therapy) , CHF, or 
other major medical illness.          
4. Prior allergic reactions attributed to compounds of 
similar chemical or biologic co mposition to 
dabrafenib  or trametinib .         
5. Concomitant use of strong inhibitors 
(eg, ketoconazole, nefazodone, clarithromycin, 
gemfibrozil) or strong inducers ( eg, rifampin,  
phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, St 
John’s wort) of CYP3A4 or CYP2C8 .  For a full 
list of  excluded  drugs see  Section  4.1.[ADDRESS_1105701] dose of study treatment .         
9. EKG with QTcB ( Bazett’s  formula) >  480 ms 
done within 14  days of enrollment          
10. Interstitial lung disease or pneumonitis.          
11. A history of  retinal vein occlusion  (RVO).           
IRB-[ADDRESS_1105702]  2018;  Amendment  8 12. Congestive heart fauilure NYHA  Class III or 
worse  (Marked limitation of physical activity .  
Comfortable at rest .  Less than ordinary activity 
causes fatigue, palpit ation, or dyspnea.)          
13. A history of acute coronary syndromes (including 
myocardial infarction or unstable angina), 
coronary angioplasty, or stenting within 6  months  
or a history or evidence of current  clinically 
significant uncontrolled arrhythmias or 
intra-cardiac defibrillators or abnormal cardiac 
valve morphology ( ≥ Grade  2) documented by 
[CONTACT_6751].   Subjects with Grade  1 
abnormalities (ie,  mild regurgitations/stenosis) 
may be entered.   Subject s with moderate valvular 
thickening are not  eligible. Subjects with atrial 
fibrillation controlled for >  30 days prior to 
dosing are eligible.          
14. Prior systemic anti -cancer treatment 
(chemotherapy, im munotherapy, biologic therapy, 
vaccine therapy or investigational treatment 
within [ADDRESS_1105703]’s safety, obtaining informed consent, or 
compliance with study procedures.          
16. A history of Hepatitis  B virus (HBV) or 
Hepatitis  C virus (HCV) infection.  Subjects with 
laboratory evidence of cleared HBV and/or HCV 
will be allowed.           
IRB-[ADDRESS_1105704]  2018;  Amendment  [ADDRESS_1105705] is [ eligible  /  ineligible ] for 
participation in the study .  This study is approved by [CONTACT_298249], the Stanford IRB, and has finalized financial and contractual 
agreements as required by [CONTACT_114054]’s Research Management Group .   
Treating Physician Signature:  [CONTACT_1782]:  
Printed Name:  
 
[CONTACT_138690]:  Date:  
Printed Name:  
 
[CONTACT_115211]:  Date:  
Printed Name:  
[CONTACT_1744]-[ADDRESS_1105706]  2018;  Amendment  [ADDRESS_1105707] or research file .   
3.3 Study Timeline  
Primary Completion:  
We estimate the study will reach primary completion 27  months from the time the study 
opens to accrual.  
Study Completion:  
The study  will reach study completion [ADDRESS_1105708]  a diagnosis of ameloblastoma  pathologically confirmed  by [CONTACT_200980]’s department of pathology .  The mutational status of BRAF in the 
tumor must be determined  by [CONTACT_31617] C LIA-certified lab using standard techniques .  These 
may include, for example, Sanger sequencing, SNaPshot platform, immunohistochemistry, 
Foundation One tests, etc.) .  While we are primarily expecting  to identify V600 E 
mutations, other BRAF mutations kn own to confer sensitivity to  dabrafenib   are acceptable 
if approved by [CONTACT_26848].  
Every patient must have baseline blood chemistries and counts and other eligibility criteria 
as defined in Section  [ADDRESS_1105709] v1.1  {Eisenhauer, 2009 } 
measurements are at the discretion of the local investigator .  These will typi[INVESTIGATOR_381518] a 
contrast  enhanced CT or MRI of the relevant anatomy , but PET -CT is also appropriate if 
the  lesion is evaluable by [CONTACT_10052] -CT per RECIST v1.1 criteria .  To maintain consistency of 
data and quality of science, whatever imaging modality is used at baseline for each patient 
should be used throughout the trial.   Photographic documentation is encouraged but cannot 
substitute for imaging.  
The starting dose for all patients will be :   
Dabrafenib, [ADDRESS_1105710] 2  hour s 
after a meal .  Dabrafenib comes as 75  mg and 50  mg capsules .  Therefore the initial dose 
will be two 75  mg capsules as specified above .  The second dose of dabrafenib (150  mg) 
should be administered approximately [ADDRESS_1105711]  2018;  Amendment  [ADDRESS_1105712] the option to resume the dabrafenib  and trametinib  at the d ose they were receiving 
immediately prior to surgery  if  ALL of the following criteria  are met:   
1. Prior to surgery the patient  did not have AEs or progression which necessitated  
dabrafenib  or trametinib  cessation.   
2. The patient has recovered from s urgery without unexpected complication.   
3. At least [ADDRESS_1105713] be informed as soon as possible about any medication taken from the 
time of screening until the end of investigational drug administration .  Documentation of  
concomitant medication(s), includi ng dietary supplements, taken during the study will be 
recorded in the  patient medical record according to the schedule specified in  Section  9.  
The minimum requirement is that drug name, dose, and the dates of administration are to 
be recorded .  
Subject s should receive full supportive care during the study, including transfusions of 
blood and blood products, and treatment with antibiotics, anti -emetics, anti -diarrheals, and 
analgesics, and other care as deemed appropriate, and in accordance with their in stitutional 
IRB-[ADDRESS_1105714]  2018;  Amendment  8 guidelines .  Use of anticoagulants such as warfarin is permitted however, c aution should 
be exercised  and additional International Normalized Ratio (INR) monitoring is 
recommended when dabrafenib is used concomitantly with warfarin .  See Sectio n 4.1.3 for 
guidelines concerning concomitant  warfarin and dabrafenib administration.  
Radiation skin injury has been reported with concurrent use of dabrafenib and radiation .  It 
is recommended that dabrafenib and trametinib be held for 7  days before and 2 days after 
XRT .  
Medicinal products that increase gastric pH should be used with caution when 
administered with dabrafenib .  See Section  4.1.3 for details.   
4.1.2 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_801014]  ( see T able 2 below ) and il licit drugs within 28 days or 
5 half-lives, whichever is shorter, prior to and during  da brafenib study treatment . will not 
be allowed .  
The following medications or non -drug therapi[INVESTIGATOR_801015]:   
 Other anti -cancer therapi[INVESTIGATOR_014];   
 Other investigational drugs;   
 Herbal remedies ( eg, St John’s  wort);   
 Dabrafenib is metabolized primarily by [CONTACT_13439] P450 (CYP) 2C8 and CYP3A4 .  
Co-administration of dabrafenib with ketoconazole, a CYP3A4 inhibit or, or with 
gemfibrozil, a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71% and 
47%, respectively .  Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8  
(see list in the table below)  may only be used under special circumstances (e.g .  as a 
single use fo r a procedure) while treatment with study drug is interrupted as they may 
alter dabrafenib concentrations ;  consider therapeutic substitutions for these 
medications .  Approval of the protocol principal  investigator [INVESTIGATOR_801016] .  
IRB-[ADDRESS_1105715]  2018;  Amendment  8 Table  2 :  Prohibited Medications  
PROHIBITED – Strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib 
may be decreased  
Class/Therapeutic Area  Drugs/Agents  
Antibiotics  Rifamycin class agents ( eg, rifampin, rifabutin, rifape ntine),  
Anticonvulsant  Carbamazepi[INVESTIGATOR_050],  oxcarbazepi[INVESTIGATOR_283567], phenytoin, 
s-mephenytoin  
Miscellaneous  bosentan, St -John’s wort  
PROHIBITED – Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib 
may be increased  
Class/Therapeuti c Area  Drugs/Agents  
Antibiotics  Clarithromycin, telithromycin, troleandomycin  
Antidepressant  Nefazodone  
Antifungals  Itraconazole, ketoconazole, posaconazole, voriconazole  
Hyperlipi[INVESTIGATOR_377461], saquinavir, atazanavir  
Miscellaneous  Conivaptan  
 
4.1.3 Medications to be used  with Caution  
The following medications should be used with caution as their concentrations may be 
altered by [CONTACT_800869]:  
 Drugs that are moderate inhibitors or indu cers of CYP3A and CYP2C8 as they may 
alter concentrations of dabrafenib.  
 Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam 
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate) .  Dabrafenib is an in vitro 
inducer of CYP2B6 and ot her enzymes such as CYP2C8, CYP2C19, UDP -glucuronyl 
transferases .  Transporters may also be affected .  Co-administration of dabrafenib and 
medications which are affected by [CONTACT_483039] (including warfarin) 
and transporters may result in loss of efficacy .  If co-administration of these 
medications is necessary, investigators should monitor subjects for loss of efficacy or 
consider substitutions of these medications .  A partial list of these medications is 
provided in  Table 2 above .   
 Thera peutic level dosing of warfarin can be used with close monitoring of PT/INR by 
[CONTACT_779] .  Warfarin exposure has been shown to decrease (37% decrease) due to 
dabrafenib -mediated enzyme induction .  Conversely, if dabrafenib dosing is reduced, 
interrupted, or  discontinued, warfarin exposure may be increased .  Thus, warfarin 
dosing may need to be adjusted based on PT/INR during and after treatment with 
dabrafenib .  Prophylactic low dose warfarin may be given to maintain central catheter 
patency .   
IRB-[ADDRESS_1105716]  2018;  Amendment  8   Infrom Dabraf enib solubility is pH -dependent with decreased solubility at higher pH .  
Drugs such as proton pump inhibitors that inhibit gastric acid secretion to elevate 
gastric pH may decrease the solubility of dabrafenib and reduce its bioavailability .  No 
clinical s tudy has been conducted to evaluate the effect of pH on dabrafenib 
pharmacokinetics .  In an ad -hoc analysis, no differences in C max and AUC were noted 
between subjects who reported taking pH -elevating products relative to other subjects .  
Due to the theore tical risk that pH -elevating agents may decrease oral bioavailability 
and exposure to dabrafenib, these medicinal products that increase gastric pH 
should be used with caution when administered with dabrafenib.  
4.[ADDRESS_1105717] .  It comes  in 50  mg and 75  mg capsules .  Active ingredient :  
dabrafenib .  Inactive ingredients :  colloida l silicon dioxide, magnesium stearate, 
microcrystalline cellulose .  Capsule shells contain :  hypromellose, red iron oxide (E172), 
titanium dioxide (E171).  
Trametinib is a FDA -approved  kinase inhibitor for the treatment of patients with 
unresectable or meta static melanoma with BRAF -V600E or -V600K mutations as detected 
by [CONTACT_13247] -approved test .  Tablets are supplied as 0.5  mg and 2  mg tablets for oral 
administration .  Each 0.5  mg tablet contains 0.5635  mg trametinib dimethyl sulfoxide 
equivalent to 0.5  mg of trametinib non -solvated parent .  Each 2  mg tablet contains 
2.254  mg trametinib dimethyl sulfoxide equivalent to 2  mg of trametinib non -solvated 
parent .  The inactiv e ingredients are t ablet core:  mannitol, microcrystalline cellulose, 
hypromellose, croscarm ellose sodium, magnesium stearate (vegetable source), sodium 
lauryl sulfate, colloidal silicon dioxide ;  and c oating :  hypromellose, titanium dioxide, 
polyethylene glycol, polysorbate 80 (2  mg tablets), iron oxide yellow (0.5  mg tablets), iron 
oxide red (2  mg tablets).  
Dabrafenib  and trametinib  will be dosed as specified in Section  [ADDRESS_1105718]  2018;  Amendment  [ADDRESS_1105719] operating 
procedures  of the investigational pharmacies of each collaborating institution ’s pharmacy .  
Drug accountability w ill similarly be according to each institution’s standard operating 
procedures . 
5.[ADDRESS_1105720].  Study 
medication is to be stored at the temperature specified on the label.  Maintenance of a 
temperature log (manual or automated) is required.  Access to and administration of 
dabrafenib and trametinib will be limited to the investigator and authorized site staff.   
6.0 DOSE MODIFICATIONS  
6.1 Dose Modification for General Toxicities  
General guidelines regar ding management and dose reduction for adverse events that are 
considered by [CONTACT_801038] t able below .  These guidelines are intended 
primarily for toxi cities not easily managed with routine supportive care .  For example, 
alopecia is not an indication for dose modification, nor is grade 2 nausea and vomiting that 
can be easily managed with anti -emetics .   
Table 3 :  Recommended dabrafenib and trametinib do se level reductions  
DABRAFENIB  TRAMETINIB  
Dose Level  Dose/Schedule  Dose Level  Dose/Schedule  
Full dose  [ADDRESS_1105721]  2018;  Amendment  8 Table 4 :  Dose Modification Guidelines - General  
CTCAE Grade  Occurance  Action and Dose Modification  a,b 
Grade 1 or 
Grade  2 
(tolerable)  N/A Continue study  treatment at same dose level (no dose 
modification) and monitor as clinically indicated  
Grade 2 
(Intolerable) or  
Grade [ADDRESS_1105722], 2nd or 
3rdoccurrence  Interrupt study treatment until toxicity resolves to ≤  grade  [ADDRESS_1105723] occurrence  Interrupt study treatment until toxicity resolves to ≤ grade  1 
or baseline then restart at next lower dose level or 
discontinue at discretion of investigator  
2nd occurrence  Interrupt study treatment until toxicity resolves to ≤ grade  [ADDRESS_1105724] occurrence  Discontinue treatment  
a. Treatment should be discontinued if more than 3 dose reductions are required  
b. Approval from the protocol PI [INVESTIGATOR_801017]  ≥ 21 days  
When an individual’s adverse reactions are under effective management, dose re -escalation 
following the same dosing steps as de -escalation may be considered .  
These are general guidelines and investigators should always use clinical judgmen t in 
determining dose adjustments for any individual patient .  Some toxicities may require 
hospi[INVESTIGATOR_194943], additional work -up, and consultation with a specialist 
before treatment can be restarted .  Specific adverse events and recommended  management 
include  the following:   
6.[ADDRESS_1105725] in patie nts taking dabrafenib and trametinib  
6.2.1 Plantar - Palmar Erythrodysesthesia  (Hand foot syndrome, PPES) – Measures for 
PPES should include:   
Lifestyle modification :  avoidance of hot water ;  traumatic activity ;  constrictive 
footwear ;  or excessive friction on the skin .  Adopt  the use of thick cotton socks and 
gloves, and shoes with padded insoles .  
Symptomatic treatments :  apply moisturizing creams frequently ;  topi[INVESTIGATOR_681711] 
(eg, urea 20  to 40% cream ;  salicylic  acid 6%;  tazarotene  0.1%  cream ;  
fluorouracil  5% cream), clobetasol  propi[INVESTIGATOR_16847]  0.05% ointment for erythematous  areas;  
topi[INVESTIGATOR_141056]  2%;  and/or systemic pain medication such as nonsteroidal 
anti-inflam matory  drugs  (NSAIDs);  codeine ;  and pregabalin for pain.   
Dose modification may also be required .  
IRB-[ADDRESS_1105726]  2018;  Amendment  8 6.2.2 Pancreatitis   
In the event of abdominal pain or suspected pancreatitis, amylase and lipase laboratory 
samples should be collected for confirmation of the diagno sis.  Patients should be 
closely monitored when re -starting dabrafenib after an epi[INVESTIGATOR_28547] . 
6.2.3 Uveitis  and ocular events (see below for specific guidelines)  
Ophthalmological exams will be required at baseline, Week  [ADDRESS_1105727] should be consulted if 
changes in vision develop .  However, if the visual changes are clearly unrelated to study 
treatment  (eg, allergic conjunctivitis), then monitor closely as it may be  reasonable to 
defer ophthalmic examination . 
Treatment with dabrafenib has been associated with the development of uveitis, 
including iritis .  Monitor patients for visual signs and symptoms ( such as, change in 
vision, photophobia and eye pain) during therapy .  Special attention should be given to 
retinal findings ( eg, retinal pi[INVESTIGATOR_6678]  (RPED) or retinovascular 
abnormalities (ie, branch or central retinal vein occlusions  (RVO).  Guidelines regarding 
management and dose reduction for visual changes and/or ophthalmic examination 
findings considered to be related to study treatment are provided in the below tables:  
IRB-[ADDRESS_1105728]  2018;  Amendment  8 Table 5 :  Management and Dose Modification Guidelines for Visual  Changes and/or 
Ophthalmologic Examination Findings  
CTCAE 
Grade  a Adverse Event Management  Action and Dose Modification  
  
Grade 1  b  Consult ophthalmologist 
within 7 days of onset  
  If dilated fundus examination cannot be 
performed within [ADDRESS_1105729]/ophthalmologist .  If 
subject is receiving trametinib/dabrafenib 
combination ther apy dabrafenib may be 
continued  
 If RPED and RVO excluded, continue (or 
restart) trametinib at same d ose level  
 If RPED suspected or diagnosed :  see RPED 
dose modification table Y below ;  report as 
SAE  if diagnosed  
 If RVO diagnosed :  Permanently discontinue 
trametinib and report as SAE  
 
 Grade 2 and  
 Grade 3   Consult ophthalmologist 
immediately  
 Interrupt t rametinib .  If 
subject is receiving 
trametinib/dabrafenib 
combination therapy 
dabrafenib may be continued   If RPED and RVO excluded,  restart trametinib at 
same dose level  
 If RPED diagnosed , see RPED dose 
modification table below ;  report as SAE  
 If RVO diagn osed:  Permanently discontinue 
trametinib  and report as SAE  
  
Grade 4   Consult ophthalmologist 
immediately  
 Interrupt trametinib .  If 
subject is receiving 
trametinib/dabrafenib 
combination therapy 
dabrafenib may be continued   If RPED and RVO excluded,  may consider 
restarting trametinib at same or reduced dose 
after discussion with study medical monitor  
 If RVO or RPED diagnosed, permanently 
discontinue trametinib and report as SAE  
c. Refers to CTCAE Version 4.0 ‘Eye disorders – Other, specify’  
d. If visual chan ges are clearly unrelated to study treatment ( eg, allergic conjunctivitis), monitor closely but 
ophthalmic examination is not required.  
IRB-[ADDRESS_1105730]  2018;  Amendment  8 Table 6 :  Recommended dose modifications for trametinib for retinal pi[INVESTIGATOR_789320] (RPED)  
CTCAE Grade a Action and Dose Modification  
Grade  1 RPED  (Asymptomatic ;  clinical 
or diagnostic observations only)   Continue treatment with retinal evaluation monthly 
until resolution .  If RPED worsens follow instructions 
below  
 
Grade  2-3 RPED  (Symptomatic with  
mild to  moderate decrease in visual acuity ;  
limiting instrumental ADL)  
  Interrupt trametinib  
 Retinal evaluation monthly  
 If improved to ≤ Grade 1, restart trametinib at lower 
dose (reduced by 0.5  mg) or discontinue in patients 
taking trametinib 1  mg daily  
e. Refe rs to CTCAE Version 4.0 ‘Retinopathy’  
6.2.[ADDRESS_1105731] been observed in subjects receiving dabrafenib monotherapy, 
and is increased in incidence and severity in subjects receiving dabrafenib in combinat ion 
with trametinib .  In a minority of cases the pyrexia was accompa nied by [CONTACT_801039] ;  dehydration ;  hypotension ;  and dizziness or weakness .  
Subjects should be instructed on the importance of immediately reporting febrile 
epi[INVESTIGATOR_1841] .  In the event of a fever, the subject should be instructed to take anti -pyretics 
(eg, ibuprofen or acetaminophen) as appropriate to control fever .  The use of oral 
corticosteroids should be considered in those instances in which anti -pyretics are 
insuffici ent.  Monitor serum creatinine and other evidence of renal function during and 
following severe events of pyrexia.   
Guidelines regarding management and dose modifications for pyrexia considered to 
be related to study treatment provided below.   
IRB-[ADDRESS_1105732]  2018;  Amendment  8 Table 7:  Ma nagement and Dose Modification Guidelines for Pyrexia  
Adverse 
Event  Adverse Event Management  Action and Dose Modification  
Pyrexia : a All Events:  
 Clinical evaluation for infection and 
hypersensitivity  c  
 Laboratory work -up c 
 Hydration as required  d 
1st Event b: 
 Administer anti -pyretic treatment  as 
clinically indicated and initiate prophylactic 
treatment if associated with rigors, renal 
failure, dehydration or hypotension  e 
2nd Event  f 
 Within 3 days of onset of pyrexia  
o Optimize anti -pyretic therapy  
o Conside r oral corticosteroids (ie, 
prednisone 10  mg) for at least 5  days or as 
clinically indicated  f 
Subsequent Events :   
 Within 3 days of onset of pyrexia:  
o Optimize oral corticosteroid dose as 
clinically indicated for recalcitrant 
pyrexia  f  
o If corticosteroids have been tapered and 
pyrexia recurs, restart steroids  
o If corticosteroids cannot be tapered consult 
medical monitor  1st Event:   
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib at the same dose level  
o If fever  was associated with rigors, renal 
failure, dehydration or hypotension, 
reduce dabrafenib by [CONTACT_30560]  g 
2nd Event:  
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib at the same dose level  
o If fever was asso ciated with rigors, renal 
failure, dehydration or hypotension, 
reduce dabrafenib by [CONTACT_30560]  g 
Subsequent Events:  
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib reduced by [CONTACT_30560]  g 
 If dabrafenib  must be reduced to <  50 mg 
BID, permanently  discontinue 
dabrafenib.  Trametinib may be 
continued  
a. Pyrexia is defined as a body temperature equal to or above 38.5 Celsius or 101.3ºFahrenheit.   
b. For subjects experiencing pyrexia complicated by [CONTACT_483021] , severe chills, etc., a clinical evaluation and laboratory work -up is 
mandatory for each event;  anti -pyretic treatment should be started immediately at the first occurrence and prophylactic 
anti-pyretic treatment is recommended  
c. Thorough clinical exami nation for signs and symptoms of infection or hypersensitivity is required;  laboratory work -up 
should include full -blood -count, electrolytes, creatinine, blood urea nitrogen (BUN), C -reactive protein (CRP), 
liver-function tests, blood culture, and urine c ulture.  
d.   Oral hydration should be encouraged in subjects without evidence of dehydration.  Intravenous hydration is recommended 
in subjects experiencing pyrexia complicated by [CONTACT_114475]/hypotension.  
e.   Anti-pyretic treatment may include acetaminoph en, ibuprofen, or suitable anti -pyretic medication according to institutional 
standards.  Prophylactic anti -pyretic treatment may be discontinued after three days in the absence of pyrexia  
f.  In subject experiencing pyrexia complicated by [CONTACT_483021], severe c hills, etc., which cannot be controlled with anti -pyretic 
medication, oral corticosteroids should be started at the 2nd event and doses should be gradually increased for subsequent 
events.  
g.   Dabrafenib should be reduced by [CONTACT_801040] [INVESTIGATOR_801018], severe chills, etc., 
which cannot be managed by [CONTACT_801041].  Escalation of dabrafenib is allowed 
if no epi[INVESTIGATOR_482962] [ADDRESS_1105733]  2018;  Amendment  8 6.2.6 Malignancies  
Cuta neous squamous cell carcinoma ( cuSCC)  
Cases of cuSCC (which include those classified as keratoacanthoma or mixed 
keratoacanthoma subtype) have been observed in subjects treated with dabrafenib .  
Approximately 70 % of events occ urred within the first [ADDRESS_1105734]  2018;  Amendment  8 Table 8 :  Management and Dose Modification Guidelines for Ren al Insufficiency  
Serum Creatinine 
Level  Adverse Event Management  Action and Dose 
Modification  
Serum creatinine 
increase >  0.2 mg/dL 
(18 umol/L)  but 
 0.5 mg/dL 
(44 umol/L) above 
baseline   Recheck serum creatinine within 1  week  
 Serum creatinine increase > 1  week :  contact [CONTACT_801042] .  If elevation persists beyond 4  week s, 
recommend evaluation (consider renal biopsy) for etiology ;  
consider nephrology consultation.  
 If pyrexia is present, treat pyrexia as per guidelines  a  Continue study 
treatmen t at the 
same dose level  
Serum creatinine 
increase >  0.5 mg/dL 
(44 umol/L) above 
baseline or  
serum creatinine 
>2 mg/dL 
(> 177 umol/L)   Monitor serum  creatinine ≥  2 times per week  
 Hospi[INVESTIGATOR_801019]  
 If pyrexia is present, treat pyrexia per guidelines  a  
 Consult nephrologist if clinically indicated  
 Perform renal biopsy if clinically indi cated, for example:  
o Renal insufficiency persists despi[INVESTIGATOR_800818]  
o Subject has new rash or signs of hypersensitivity (such as 
elevated eosinophil count)   Interrupt study 
treatment until 
serum creatinine 
recovers to 
baseline  
 Restart with study 
treatme nt b 
a. NSAIDs can induce renal insufficiency, especially in subjects with dehydration ;  encourage oral fluids or 
consider intravenous fluids as clinically indicated .  See guidelines for pyrexia Section  
b. Investigator may restart at either the same or a  reduced dose level .  Escalation of study treatment to previous dose 
level is allowed if another epi[INVESTIGATOR_535888] [ADDRESS_1105735]  2018;  Amendment  8 6.2.10  Guidelines for Prolonged QTc  
Guidelines for dose modification and stoppi[INVESTIGATOR_801020] -prolongation are below.  
Table 9:  Withholding and Stoppi[INVESTIGATOR_482935] B-Prolongation  
QTc-
Prolongation  a  Action and Dose Modification  
 QTcB   
≥ 501 msec   or 
 Uncorrected 
QT > 600 msec  
or 
 QTcB  > 530 
msec for subjects 
with bundle 
branch block   Interrupt study treatment until QTcB prolongation resolves to Grade 1 or baseline  
 Test serum potassium, calcium, phosphorus and magnesium .  If abnormal, corr ect 
per routine clinical practice to within normal limits  
 Review concomitant medication usage for a prolonged  QTc 
 If event resolves, restart study treatment at current dose level  b 
 If event does not resolve, permanently discontinue study treatments .  Consi der 
evaluation with cardiologist.  
 If event recurs, permanently discontinue study treatment  
 Consider evaluation with cardiologist  
Abbreviations:  msec = milliseconds; QTc = QT interval on electrocardiogram  
a. Based on average QTc value of triplicate ECGs.  F or example, if an ECG demonstrates a prolonged QT 
interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three 
ECGs to determine if study treatments should be interrupted or discontinued.  
b. If the QTc prolongation resolves to grade [ADDRESS_1105736]  2018;  Amendment  [ADDRESS_1105737] s receiving trametinib in combination with 
dabrafenib .  To reduce the risk of pneumonitis, subjects will be monitored closely for 
symptoms, evaluated with imaging and functional tests .  Dose modification and supportive 
care guidelines for pneumonitis are d escribed below.  
Table 10 :  Management and Dose Modification Guidelines for Pneumonitis  
CTCAE 
Grade  Adverse Event Management  Action and Dose Modification  
 
Grade 1   CT scan (high -resolution with lung windows) 
recommended  
 Clinical evaluation and laboratory wo rk-up for 
infection  
 Monitoring of oxygenation via pulse -oximetry 
recommended  
 Consultation of pulmonologist recommended   Continue trametinib at current dose  
Grade 2   CT scan (high -resolution with lung windows)  
 Clinical evaluation and laboratory work -up for  
infection  
 Consult pulmonologist  
 Pulmonary function tests –if < normal, repeat 
every 8  week s until ≥ normal  
 Bronchoscopy with biopsy and/or BAL 
recommended  
 Symptomatic therapy including corticosteroids 
if clinically indicated   Interrupt trametinib until recovery to 
grade ≤1  
 Restart with  trametinib reduced by [CONTACT_23615]  
 Escalation to previous  dose level after 
4 week s and consultation with medical 
monitor possible  
 If no recovery to grade ≤1 within 
4 week s, permanently discontinue study 
treatment  
Grade 3   CT scan (high -resolution with lung windows)  
 Clinical evaluation and laboratory work -up for 
infection  
 Consult pulmonologist  
 Pulmonary function tests -if < normal, repeat 
every 8  week s until ≥ normal  
 Bronchoscopy with biopsy and/or BAL if 
possible  
 Symptomatic therapy including corticosteroids 
as clinically indicated   Interrupt trametinib until recov ery to 
grade ≤1  
 After consultation with medical monitor, 
study treatment may be restarted reduced 
by [CONTACT_30560]  
 If no recovery to grade ≤1 within 
4 week s, permanently discontinue study 
treatment  
Grade 4   Same as grade 3   Permanently discontinue trametin ib  
6.2.12  Guidelines for Cardiomyopathy  
Across clinical trials of trametinib at the recommended dose 11% of patients developed 
evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of  normal 
with an absolute decrease in LVEF ≥  10% below baseline) and 5% demonstrated a  
decrease in LVEF below institutional lower limits of normal with an absolute decrease in 
LVEF of ≥  20% below baseline.  
IRB-[ADDRESS_1105738]  2018;  Amendment  8 Assess LVEF  before initiation of trametinib, one month after initiation and then at  
3-month int ervals while on treatment .  Withhold treatment if absolute LVEF value 
decreases by 10% from pre -treatment values and is less than the lower limit of normal .  
Permanently discontinue for  symptomatic cardiomyopathy or persistent, asymptomatic 
LVEF dysfuncti on that does not resolve within 4  week s 
Table 11 :  Combination Dose Modification Guidelines  and Stoppi[INVESTIGATOR_801021] -drop (%) or  
CTCAE grade  Action and Dose Modification  
 
Asymptomatic   
Absolute decrease of 
> 10% in LVEF 
compared  to baseline 
and ejection fraction 
below the institution’s  
LLN   Interrupt trametinib and repeat ECHO within 2  week s a,b  
 If the LVEF recovers  within 4  week s (defined as LVEF 
≥ LLN and absolute decrease ≤  10% compared to baseline)   
 Consult with [COMPANY_001] me dical monitor and request 
approval for re -start 
 If approved, re -start treatment with TMT reduced by 
[CONTACT_30560]  
 Repeat ECHO at 2, 4, 8, and 12 weeks after re -start, 
continue at intervals of 12 weeks  
 If  LVEF does not recover  within 4  week s 
    Consult wi th cardiologist  
 Permanently discontinue trametinib  
 Report as SAE  
 Repeat ECHO after 2, 4, 8, 12, and 16 weeks, or 
until resolution  
Symptomatic  c Grade 3 :  resting LVEF 
39 to 20% or >  20% 
absolute reduction from 
baseline   Permanently discontinue trametinib  
 Interrupt dabrafenib  d  
 Report as SAE  
 Consult with cardiologist  
 Repeat ECHO after 2, 4, 8, 12, and 16 weeks, or  until 
resolution  b,d Grade 4 :  resting 
LVEF  < 20% 
Abbreviations:  CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiog ram; LLN = lower 
limit of normal; LVEF = left ventricular ejection fraction;  
a. If ECHO does not show LVEF recovery after 2 weeks, repear ECHO two weeks later.  
b. If recurrent epi[INVESTIGATOR_801022], consult medica l monitor.  
c. Symptoms may include :  dyspnea, orthopenea, and other signs and symptoms of pulmonary congestion and edema.  
d. Once LVEF recovers, including resolution of symptoms, restart of dabrafenib monotherapy only can be considered 
in consultation with Novar tis medical monitor.  
IRB-[ADDRESS_1105739]  2018;  Amendment  8 6.2.13  Treatment of Study Treatment Overdose  
In the event of a dabrafenib overdose, defined as administration of more than 300  mg as a 
single dose or 600  mg per day (the highest dose tested in clinical studies to date), and/or a 
trame tinib overdose, defined as administration of more than 3.[ADDRESS_1105740] for AEs/SAEs and laboratory abnormalities .  
The investigator will use clinical jud gment to treat any overdose .  Hemodialysis is not  
expected to enhance the elimination of either dabrafenib or trametinib as both are highly 
bound to plasma proteins.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_801043] [INVESTIGATOR_801023].  
Information regarding the quantity of the excess dose as well as the duration of the 
overdosing should be documented in the case report  forms . 
7 ADVERSE EVENTS AND REPORTING PROCEDURES  
7.1 Potential Adverse Events  
7.1.1 Dabrafenib pot ential  adverse effects  
Please see  the FDA package insert for dabrafenib .  Additional  information can also be 
found in the Investigator Brochure section titled “Summary of Data and Guidance for the 
Investigator .”  Below are tables from the 2015 package summarizing anticipated  AEs:  
IRB-[ADDRESS_1105741]  2018;  Amendment  8 Table 12 :  Selected Common Adverse Reactions Occurring in > 10% (All Grades) or ≥  2% 
Grades 3 or 4) of Patients Treated with dabrafenib N = 187  
 
 
Table 1 3: Incidence of Laboratory Abnormalities Increased from Baseline Occurring a t a 
Higher Incidence in Patients Treated with dabrafenib (Tafinlar)  in a single agent melanoma 
trial [Between -Arm Difference of ≥  5% (All Grades) or ≥  2% (Grades 3 or 4)] a 
IRB-[ADDRESS_1105742]  2018;  Amendment  8 
 
 
Other clinically important adverse reactions observed in <  10% of patients (N  = 586) 
treated with dabrafenib were:  
 Gastrointestinal Disorders :  Pancreatitis .   
 Immune System Disorders :  Hypersensitiv ity manifesting as bullous rash  
 Renal and Urinary Disorders :  Interstitial nephritis.  
IRB-[ADDRESS_1105743]  2018;  Amendment  8 Table 14: Select Adverse Reactions Occurring in ≥10%  (All Grades) of 
Patients Treated with dabrafenib( tafinlar)  in Combination with Trametinib  
 
IRB-[ADDRESS_1105744]  2018;  Amendment  8 Table 15: Select Treatment -Emergent Laboratory Abnormalities Occurring at ≥10% (All 
Grades) of Patients Receiving dabrafenib (Tafinlar) in combination with trame tinib.  
 
7.1.2 Trametinib potential adverse effects  
Please see the FDA package insert for trametinib .  Additional information can also be 
found in the Investigator Brochure section titled “Summary of Data and Guidance for the 
Investigator” .  Below are tabl es from the [ADDRESS_1105745]  2018;  Amendment  8 Table 16:  Selected Adverse Reactions Occurring in ≥10% of Patients Receiving 
trametinib  (Mekinist) and at a Higher Incidence (≥ 5%) than in the Chemotherapy  
Arm  or ≥ 2% (Grades  3 or 4) Adverse  Reactions   
 
Other clinically important adverse reactions observed in less than or equal to 10% of patients 
(N = 329) treated with  Mekinist  (trametinib ) were:   
Cardiac  Disorders: Bradycardia  
Gastrointestinal  Disorders: Dry mouth  
Infections and Infestations: Folliculitis, rash pustular, cellulitis   
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis  
Nervous System Disorders: Dizziness, dysgeusia  
Ocular Disorders: Blurred vision, dry eye  
IRB-[ADDRESS_1105746]  2018;  Amendment  8 Table 17:  Percent -Patient Incidence of Laboratory Abnormalities Occurring at  
a Higher Incidence in Patients Treated With trametinib  (Mekinist)  in Trial  1  
[Between Ar m Difference of ≥  5% (All Grades) or ≥  2% (Grades 3 or 4)  a] 
 
IRB-[ADDRESS_1105747]  2018;  Amendment  8 Table 18:  Incidence of Adverse Reactions Occurring in ≥10% (All Grades) of Patients 
Receiving trametinib (MEKINIST_ with Dabrafenib and at a Higher Incidence* than in  
Patients Receiving Single -Agent Dabrafenib  
 
Other clinically important adverse reactions for trametinib observed in less than 10% of patients 
receiving trametinib in combination with dabrafenib ( N = 559) were:  
Cardiac Disorders: Bradycardia  
Musculoskeletal Disorders: Rhabdomyoly sis 
IRB-[ADDRESS_1105748]  2018;  Amendment  8 Table  19:  Treatment -Emergent Laboratory Abnormalities Occurring at ≥  10% (All  Grades) of 
Patients Receiving trametinib  (Mekinsit ) with Dabrafenib and at a Higher Incidence* than in 
Patients Receiving Single -Agent  Dabrafenib  
 
7.2    Adverse Event Reporting  
For detailed  guidan ce on reporting adverse events, refer to the  adverse event SOP  
(Appendix  B) 
Reporting  
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the 
patient has provided the main informed consent and until at least [ADDRESS_1105749]  2018;  Amendment  [ADDRESS_1105750] be reported as follow -up to the 
original epi[INVESTIGATOR_5319] 24  hours  of the investigator receiving the follow -up information .  
An SAE occurring at a different time i nterval or otherwise considered completely unrelated 
to a previously reported one should be reported separately as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the fo rm must be completed in order to provide a clinically 
thorough report .  The investigator must assess and record the relationship of each SAE to 
each specific study treatment (if there is more than one study treatment), complete the SAE 
Report Form in Engli sh, and send the completed, signed form by [CONTACT_87109] 24  hours  to the 
oncology [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623] (DS&E) department - Fax: 
([PHONE_002]) .  The original copy of the SAE Report Form and the fax confirmation sheet 
must be kept with the cas e report form documentation at the study site .  Follow -up 
information is sent to the same contact(s) to whom the original SAE Report Form was sent, 
using a new SAE Report Form stating that this is a follow -up to the previously reported 
SAE and giving the d ate of the original report .  Each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless 
of when it occurs .  The follow -up information should describe whether the event has 
resolved or c ontinues, if and how it was treated, whether the blind was broken or not, an 
whether the patient continued or withdrew from study participation.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and i s thought to be related to the [COMPANY_001] study treatment, an oncology 
[COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623] (DS&E) department associate may urgently 
require further information from the investigator for Health Authority reporting .  [COMPANY_001] 
may need to issu e an Investigator Notification (IN), to inform all investigators involved in 
any study with the same drug that this SAE has been reported .  Suspected Unexpected 
Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent 
authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as 
per national regulatory requirements in participating countries.  
Pregnancies  
To ensure patient safety, each pregnancy occurring while the patient is on study treatment 
must be rep orted to [COMPANY_001] within 24  hours  of learning of its occurrence .  The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary 
termination, details of the birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complications.  
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_36926][INVESTIGATOR_066] (DS&E) .  
Pregnancy follow -up should be  recorded on the same form and should include an 
assessment of the possible relationship to the study treatment any pregnancy outcome .  Any 
SAE experienced during pregnancy must be reported on the SAE Report Form.  
Adverse events will be graded according to  CTCAE v4.0 3.  Both Serious and Non -Serious 
Adverse Events will be clearly noted in source documentation and listed on study specific 
Case Report Forms (CRFs) .  The Protocol Director (PD) or designee will assess each 
IRB-[ADDRESS_1105751]  2018;  Amendment  8 Adverse Event (AE) to determine whether  it is unexpected according to  Section  7.1 of the 
protocol and related to dabrafenib  and trametinib .   
SAEs and all subsequent follow -up reports will be reported to the CCTO Safety Office 
regardless of the event’s relatedness to the investigation .  Followi ng review by [CONTACT_801044], any events  meeting the IRB definition of “Unanticipated  Problem ” will be 
reported to the IRB using eProtocol within 10 working days of the review, or within 5 
working days for deaths or life -threatening experiences .  SAEs will be relayed back to 
[COMPANY_001].  
7.2.1 SAE definitions  
Serious adverse event (SAE) is defined as one of the following:  
 Is fatal or life-threatening  
 Results in persistent or significant disability/incapacity  
 Constitutes a congenital anomaly/birth defe ct 
 Is medically significant, ie, defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above  
 Requires inpatient hospi[INVESTIGATOR_1081],  
Note that hospi[INVESTIGATOR_14944]:  
 Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition  
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
 Social reasons and respi[INVESTIGATOR_064]’s 
general condition  
Note that treatment on an eme rgency outpatient basis that does not result in hospi[INVESTIGATOR_286743] a SAE given above 
is not a serious adverse event  
7.[ADDRESS_1105752] is of 
childbearing potential or non -childbearing potential.  
A female of non -childbearing potential ( ie, physiologically incapable of becoming 
pregnant) is defined as any female who has had a hysterectomy, bilat eral oophorectomy 
(ovariectomy), bilateral tubal ligation or tubal occlusion, or is post -menopausal.   
A practical definition accepts menopause after 1 year without menses with an appropriate 
clinical profile, eg, age appropriate, >  45 years in the absence  of hormone -replacement 
therapy (HRT).  In questionable cases, the subject must have a follicle -stimulating 
hormone  (FSH) value >  40 mIU/mL and an estradiol value <  40 pg/mL (<  140 pmol/L).  
IRB-[ADDRESS_1105753]  2018;  Amendment  [ADDRESS_1105754] a serum β-human chorionic 
gonadotropin  (HCG) pregnancy test performed within [ADDRESS_1105755] label and the instructions of the physician, are as follows:  
 An intrauterine device with a documented fai lure rate of less than 1% per year.  
 Male partner sterilization prior to the female subject’s entry, and this male is the sole 
sexual partner for that female.  
 Complete abstinence from sexual intercourse for [ADDRESS_1105756].  Periodic abstinence (eg , calendar, ovulation, 
symptothermal, post -ovulation methods,  etc) and withdrawal are not acceptable 
methods of contraception.  
 Double -barrier contraception: condom and occlusive cap (diaphragm or cervical/vault 
caps) with a vaginal spermicidal agent (foam/gel/cream/suppository).  
Note:  Hormonal -based methods ( eg, oral contraceptives) are not permitted as 
contraception due to potential drug -drug interactions with dabrafenib.   
Female subjects who are lactating must discontinue nursing prior to the first dose of study 
treatment and must refrain from nursing throughout the treatment period and for [ADDRESS_1105757] becomes pregnant during the treatment period of the study, the study treatments 
should be stopped immediately.  
8 CORRELATIVE/  SPECIAL STUDIES  
8.1 Laboratory Correlat ive Studies  
8.1.1 Collection of Specimen(s)  
Biopsy specimens will be collected per normal institutional methods for biopsy and 
surgical resection procedures.  
8.1.2 Handling of Specimens(s)  
At the time of the baseline biopsy, endpoint biopsy, and/or resection specimen,  the tissue 
will be handled and processed by [CONTACT_801045] .  Standard morphologic assessment of the tissue 
(including H&E stain) will be performed by [CONTACT_801046], 
if possible.  
IRB-[ADDRESS_1105758]  2018;  Amendment  8 8.1.3 Shippi[INVESTIGATOR_25476](s)  
The archived biopsy or representative portions of the resection specimen, including 
formalin fixed paraffin e mbedded block and matching H&E slide, will be sent to the 
laboratory of [CONTACT_801059] at the Site Performing Correlative Study 
(Stanford  Cancer  Institute) by [CONTACT_177719] .  Once archived, the 
tissue is stable at room temperature.  
8.1.4 Site(s) Performing Correlative Study  
The Site Performing Correlative Study is the laboratory of [CONTACT_801060] at the Stanford 
Cancer Institute at the Stanford University Medical Center .  [CONTACT_87451]’s laboratory will be 
responsible for all the correlative stu dy tests.  
8.1.[ADDRESS_1105759] .  
The specimen will be given a 5 -digit number with no relationship to the subjects’  HIPPA 
data.  The key for the cod ed specimens and the patient data will be kept by [CONTACT_801047] a locked office.  
IRB-[ADDRESS_1105760]  2018;  Amendment  8 9 STUDY CALENDAR  
 Pre-
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Off-Study  d 
Dabrafenib  
 Dabrafenib will be 
administered twice daily as 
specified  in Section  4 until 
surgical resection  FOR SUBJECTS 
NOT  UNDERGOING 
SURGICAL RESECTION:  
dabrafenib will continue 
until disease progression or 
intolerance   
Trametinib  
 Trametinib will be 
administered daily as 
specified in Section  4 until 
surgical resection  FOR SUBJECTS 
NOT  UNDERGOING 
SURGICAL RESECTION:   
trametinib will continue 
until disease progression or 
intolerance   
Informed consent  X              
Demographics  X              
Medical history  X              
Biopsy of tumor for 
correlative studies  X       X g       
Surgical resection for 
patients with 
resectable tumors, and 
tissue collection for 
correlative studies          X        
Concurrent meds  X X X a  
 
Physical exam  X   X   X   X a   X a X 
Vital signs  X   X   X   X a   X a X 
Height  X              
Weight  X              
Performance status  X              
CBC w/diff, plts  X   X   X   X a   X a X 
Serum chemistry b X   X   X   X a   X a X 
EKG within [ADDRESS_1105761]  2018;  Amendment  8  Pre-
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Off-Study  d 
Adverse event 
evaluation.  See 
Section  7 for expected 
AEs and Section  6 for 
dose modification 
rules.  X   X   X   X a   X a X a 
Tumor measurements  
X Tumor measurements are repeated every 6  weeks.  After 
Week  7, tumor measurements are repeated every 
6 to 9 weeks. Documentation (radiologic) must be 
provided for patients removed from study for progressive 
disease.  X d 
Radiologic evaluation 
(CT, MRI, X -ray) 
X Tumor measurements are repeated every 6  weeks.  After 
Week  7, tumor measurements are repeated e very 
6 to 9 weeks. Documentation (radiologic) must be 
provided for patients removed from study for progressive 
disease.  X d 
Serum Pregnancy 
testing within 14  days 
of enrollment  X   
Ophthalmologic 
examination.  See 
Section  6 on 
guidelines for visual 
chang es and exam 
source sheet in 
appendix  X      X e        
a: Only for patients continuing on dabrafenib and/ or  trametinib who have not undergone surgery.   
b: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, 
phosphorus, potassium, total protein, AST, ALT, sodium.  
d: Off-study evaluation.   
e: Ophthalmologic exams to be repeated  annually.  
f: Every 3 months while on trametinib . 
g. For subjects not undergoing surgical  resection.  
 
 
10 MEASUREMENTS  
Primary Outcome Measure :  Response rate according to RECIST v1.1 at 6  week s  
 RECIST  v1.[ADDRESS_1105762]  v1.1  
 Time Frame :  6 weeks  
 Safety Issue :  Not a  safety issue  primary endpoint  
IRB-[ADDRESS_1105763]  2018;  Amendment  8 10.1 Primary and Secondary Outcome measur es 
The primary endpoint will be tumor response rate (CR + PR)  at [ADDRESS_1105764]  v1.1 criteria  {Eisenhauer, 2009} , knowing that since this patient 
population will include presurgical subjects, we will be unable to obtain respons e 
confirmation following the surgical resection of tumors . {Eisenhauer, 2009 #311}  
10.1.[ADDRESS_1105765] secondary endpoint of response will be evaluation of 
extent of tumor necrosis by H&E slide review .  This will be performed on either the 
endpoint biopsy or the resection specimen .   
10.2.3  Measurement Methods  
Routine H&E slide review will be used to measure extent of tumor necrosis for purposes of 
response assessment .  Percentage of tumor necrosis by [CONTACT_801048] .  The biopsy slide or multiple slides of 
the resection specimen will be examined and the volume of the necrosis compared to the 
volume of the total tumor will be determined by [CONTACT_801049], in i ncrements of 10%, will be determined .  In 
addition to measuring tumor necrosis the slide review will also estimate therapy effect on 
intact cells by [CONTACT_801050] -associated nuclear atypia.  
IRB-[ADDRESS_1105766]  2018;  Amendment  [ADDRESS_1105767] with tumor necrosis evaluation 
experience.  
10.3 Secondary Outcome – Proliferation index  
A second secondary outcome will be proliferation index as measured by [CONTACT_15915]67 percent 
positivity at the time of endpoint biopsy or surgical resection .  We intend to use this 
outcome as measured with immunohistochemistry with criteria establis hed for assessment 
of proliferation index for other tumors .   
10.3.[ADDRESS_1105768] 
with proliferation index evaluation experience.  
10.4 Secondary Outcome – Phosphorylation of MEK/ERK  
A second secondary outcome will be expression of phosphorylation of MEK and ERK as 
measured by [CONTACT_51213] -MEK/ERK positivity at the time of endpoint biopsy or surgical 
resection .  We intend to use this outcome as m easured with immunohistochemistry using 
antibodies specific for phospho -MEK/ERK and total MEK/ERK (either phosphorylated or 
IRB-[ADDRESS_1105769]  2018;  Amendment  8 un-phosphorylated) with criteria established for assessment of protein expression by 
[CONTACT_801051] .   
10.4.1  Measur ement Definition  
The definition we will use for the second secondary endpoint of response will be evaluation 
of protein expression by [CONTACT_9064] .  This will be performed on the initial 
pre-treatment biopsy and either the endpoint biopsy or the re section specimen.  
10.4.2  Measurement Methods  
Immunohistochemistry evaluation for MEK/ERK will be performed in the laboratory of 
[CONTACT_801061] on the initial pre -treatment biopsy and either the endpoint biopsy or the 
resection specimen .  Immunohistochemistry wi ll be scored by [CONTACT_801052] .  The results 
of the immunohistochemical analysis will be expressed as both raw data in addition to a 
ratio between pre - and post - treatment .  All pathological evaluations will be done centrally 
by [CONTACT_801053] - investigators, Robert West and Jonathan Pollack or their designees.  
10.4.3  Measurement Time Points  
Immunohistochemistry evaluation for MEK/ERK for this secondary endpoint will be a t the 
time of the endpoint biopsy or the surgical resection.  
10.4.4  Response Review  
Immunohistochemistry evaluation for MEK/ERK will be centralized review by [CONTACT_801054]-investigator, Robert West and Jonathan Pollack and at least one designee with 
substantial ex perience with protein expression evaluation .  Disagreements concerning 
response assessment between the PI [INVESTIGATOR_801024] a board 
certified pathologist with protein expression evaluation experience.  
11 REGULATORY CONSIDERATIONS  
11.1 Institutional Review of Protocol  
The protocol, the proposed informed consent and all forms of participant information 
related to the study (e.g .  advertisements used to recruit participants) will be reviewed and 
approved by [CONTACT_801055] 
(SRC) .  Any changes made to the protocol will be submitted as a modification and will be 
approved by [CONTACT_14226] .  The Protocol Director will disseminate the 
protocol amendment information to a ll participating investigators .  All participating sites 
will similarly have the  informed consent document and protocol  reviewed and approved by 
[CONTACT_801056] .  There is to be only one version of the 
protocol to be used ac ross all participating sites and no site can individually modify or 
amend the protocol at their site alone .  That is, al l protocol amendments and modifications 
must be reviewed and approved by [CONTACT_59207] l institutions’ relevant review boards.  
11.2 Data and Safety Monit oring Plan :   
The Stanford Cancer Institute Data and Safety Monitoring Committee (DSMC) will be the 
monitoring entity for this study .  The DSMC will audit study -related activities to determine 
whether the study has been conducted in accordance with the pro tocol, local standard 
operating procedures, FDA regulations, and Good Clinical Practice (GCP) .  This may 
IRB-[ADDRESS_1105770]  2018;  Amendment  8 include review of the following types of documents participating in the study :  regulatory 
binders, case report forms, eligibility checklists, and sour ce documents .  In addition, the 
DSMC will regularly review serious adverse events and protocol deviations associated with 
the research to ensure the protection of human subjects .  Results of the DSMC audit will be 
communicated to the IRB s of all participat ing institutions and  the appropriate regulatory 
authorities at the time of continuing review, or in an expedited fashion, as needed.  
11.[ADDRESS_1105771] protected HIPAA complian t 
web- based electronic data capture  system .  Prior to opening this study at any site, case 
report forms for the collection of a ll relevant required data  will be developed and relevant 
site staff trained on the access and use of REDCap .  Eligibility for ea ch patient enrolled 
will be confirmed by [CONTACT_978] [INVESTIGATOR_801025] .  The Protocol Director, or his/her designee, will 
prepare and maintain adequate and accurate participant case histories with observations and 
data pertinent to the study .  At each participating site, that site’s PI [INVESTIGATOR_801026] .  All sites should also be able to readily access actual primary 
documentation, either electronically or in paper form, for on-site audit purposes.  
11.3.2  Data  Submission responsibility  
It is the responsibility of each site PI [INVESTIGATOR_801027] .  For the purposes of site data submission compliance, data will be considered 
delinquent and such delinquency reported to that site’s IRB if the data for any required 
routine  evaluation is not  submitted within [ADDRESS_1105772], or 
assessment has been completed or resulted.  
11.3.3  Multicenter Guidelines  
The overall PI [INVESTIGATOR_801028] .   
12 STATISTICAL CONSIDERATIONS  
12.1 Statistical Design  and primary analysis  
We propose a two stage Optimal design per Simon , et al.  (Sim on   R ,1989 .  Controlled 
Clinical Trials .  10:1-10), and using the UNC calculator:  
http://www.cscc.unc.edu/cscc/aivanova/SimonsTwoStageDesign.aspx  
The null hypothesis that the  true response rate is 0.[ADDRESS_1105773] stage, 9 evaluable patients will be accrued .  If there is less than one 
response (defined in Section  10.1)  in these 9 patients, the study will be stopped .  If at the 
time of the 9th patient’s enrollment there has not been at least one centrally  documented 
response , accrual  will stop until responses have been centrally determined for the first nine 
patients .  Otherwise, [ADDRESS_1105774]  2018;  Amendment  [ADDRESS_1105775] stage and up to 
10 patients in the second stage to account for patient drop -out / uneavaluable pati ents.  This 
design yields a type  I error rate of 0.0466 and power of 0.8122 when the true response rate 
is 0.25 .  We believe that anything below a response rate of 25% would not be clinically 
meaningful given the potential risks of dabra fenib  and trametinib .  The likelihood of 
stoppi[INVESTIGATOR_801029] 0.63 .  A response rate of 25% or higher, 
in the context of other promising secondary endpoint  results such  as a high % of tumor  
necros is, would warrant further s tudy.  
12.2 Secondary Analysis  
We will determine secondary responses for :  1) tumor necrosis ;  2) prolife ration index ;  and 
3) ERK/MEK phos phorylation .  These assays will be exploratory and not subjected to a 
prospective statistical plan for analysis .  Tumor nec rosis % will be estimated according  the 
standard surgical pathology techniques.  Proliferation index will be measured  by 
[CONTACT_801057] [ADDRESS_1105776]’s lab 
according to his lab’s SOPs.   See Section  10 for details.  
12.3 Sample Size  
11 to 21 patients  (9 to 17 evaluable pateints) .  See Section  12.1 
12.4 Accrual estimates   
We estimate 3  to 6 patients will be accrued among collaborating institutions annually .  This 
is a very rare disease, incidence 0.5/ million estimated .  Stanford sees and evaluates outside 
pathology on about [ADDRESS_1105777] 2/[ADDRESS_1105778] s tage of accrual.  Should less than 2/[ADDRESS_1105779]  2018;  Amendment  8 13 REFERENCES  
Acosta D , Affolder T, Akimoto H,  et al.  (2003) .  “Search for the supersymmetric partner of the 
top quark in dilepton events from pp collisions at square root o f s=1.8 TeV. ”  Phys Rev Lett .  
90(25 Pt 1) :251801.  
Amzerin M , Fadoukhair Z, Belbaraka R , et al.  (2011) .  “Metastatic ameloblastoma responding to 
combination chemotherapy :  case report and review of the literature. ”  J Med Case Rep .  5:491. 
Anand  SV, Davey WW, Cohen B , et al.  (1967) .  “Tumours of the jaw in West Africa .  A review 
of 256 patients. ”  Br J Surg .  54(11) :901-917.  
Barnes L .  (2005) .  Pathology and Genetics of Head and Neck Tumours , IARC :296-300. 
Becelli R , Carboni A, Cerulli G,  et al.  (2002) .  “Mandibular ameloblastoma :  analysis of surgical 
treatment carried out in 60 patients between 1977 and 1998. ”  J Craniofac Surg .  13(3) :395-400;  
discussion 400.  
Becelli R , Morello R, Renzi G,  et al.  (2011) .  “Treatment of recurrent mandibular  ameloblastoma 
with segmental resection and revascularized fibula free flap. ”  J Craniofac S urg.  
22(3) :1163 -1165 . 
Brastianos PK, et al.  (2016) .  “Dramatic Response of BRAF -V600E Mutant Papi[INVESTIGATOR_801030] .”  J Natl Cancer Inst .  108. 
Bhasker S .  (1981) .  “Synopsis of Oral Pathology. ” 
Brazis  PW, Miller NR, Lee AG,  et al.  (1995) .  "Neuro -ophthalmologic Aspects of 
Ameloblastoma."  Skull Base Surg .  5(4):233-244. 
Brown  NA, Rolland D, McHugh JB,  et al.  (2014) .  “Activating FGFR2 -RAS-BRAF mutations in 
ameloblastoma. ”  Clin Cancer Res .  20(21) :5517 -5526.  
Carlson  ER, Marx RE.  (2006) .  “The ameloblastoma :  primary, curative surgical management. ”  J 
Oral Maxillofac Surg .  64(3) :484-494. 
Chai Y , Jiang X, Ito Y,  et al.  (2000) .  “Fate of  the mammalian cranial neural crest during tooth 
and mandibular morphogenesis. ”  Development .  127(8) :1671 -1679 . 
Ciment  LM, Ciment AJ. (2002) .  "Malignant ameloblastoma metastatic to the lungs 29 years after 
primary resection :  a case report."  Chest .  121(4):1359 -1361 . 
Cusack  JW.  (1827) .  “Report of the amputations of the lower jaw. ”  Dublin Hosp Rec .  4:1-38. 
Daley  TD, Wysocki GP, Pringle GA , et al.  (1994) .  “Relative incidence of odontogenic tumors 
and oral and jaw cysts in a Canadian population. ”  Oral Surg Oral Med Oral Pathol .  
77(3) :276-280. 
Eisenhauer  EA, Therasse P, Bogaerts J,  et al.  (2009) .  “New response evaluation criteria in solid 
tumours :  revised RECIST guideline (version 1.1). ”  Eur J Cancer .  45(2) :228-247. 
Eliasson  AH, Moser RJ, 3rd, Te nholder MF .  (1989) .  ”Diagnosis and treatment of metastatic 
ameloblastoma. ”  South Med J .  82(9) :1165 -1168 . 
Escandell I, et al.  (2015) .  “Effective treatment with Dabrafenib and Trametinib for a 
BRAF -mutated metastatic dedifferentiated malignant spi[INVESTIGATOR_801031]. ”  J Eur Acad 
Dermatol Venereol . 
Flaherty KT, et al.  (2012) .  “Improved survival with MEK inhibition in BRAF -mutated 
melanoma .”  N Engl J Med .  367:107-114. 
Gall JA, Sartiano GP, Shreiner DP , et al.  (1975) .  “Ameloblastoma of the mandible w ith 
pulmonary metastasis. ”  Oncology 32(3 -4):118-126-126. 
IRB-[ADDRESS_1105780]  2018;  Amendment  8 Gardner  DG, Pecak AM. (1980) .  “The treatment of ameloblastoma based on pathologic and 
anatomic principles. ”  Cancer .  46(11) :2514 -2519 .  
Gerzenshtein J , Zhang F, Caplan J,  et al.  (2006) .  “Immedia te mandibular reconstruction with 
microsurgical fibula flap transfer following wide resection for ameloblastoma. ”  J Craniofac 
Surg .  17(1) :178-182. 
Gortzak  RA, Latief BS, Lekkas C,  et al.  (2006) .  “Growth characteristics of large mandibular 
ameloblastoma s:  report of 5 cases with implications for the approach to surgery. ”  Int J Oral 
Maxillofac Surg . 35(8) :691-695. 
Grunwald V , Le Blanc S, Karstens JH,  et al.  (2001) .  “Metastatic malignant ameloblastoma 
responding to chemotherapy with paclitaxel and carbo platin. ”  Ann Oncol .  12(10) :1489 -1491 . 
Hasim  FW, Poon CC, Smith AC .  (2007) .  “Prolonged survival with confirmed metastatic 
pulmonary ameloblastoma. ”  Int J Oral Maxillofac Surg .  36(10) :953-955. 
Hauschild A, et al.  (2012) .  “Dabrafenib in BRAF -mutated m etastatic melanoma :  a multicentre, 
open -label, phase 3 randomised controlled trial. ”  Lancet .  380(9839) :358-365. 
Hertog D , Bloemena E, Aartman IH,  et al.  (2012) .  “Histopathology of ameloblastoma of the 
jaws;  some critical observations based on a 40  years single institution experience. ”  Med Oral 
Patol Oral Cir Bucal .  17(1) :e76-82. 
Ivy RH , Churchill HR. (1930) .  “The need of a standardized surgical and pathological 
classification of tumors and anomalies of dental origin. ”  Am Assoc Dent Sch Trans .  7:240-245. 
Kaye FJ, et al.  (2015).  “Clinical and radiographic response with combined BRAF -targeted 
therapy in stage 4 ameloblastoma.”  J Natl Cancer Inst .  107(1):378 . 
Kurppa KJ, CatonJ, Morgan PR, et al.  (2014) .  “High frequency of BRAF -V600E mutations in  
ameloblastoma. ”  J Pathol .  232(5) :492-498. 
Larsson A , Almeren H. (1978) .  "Ameloblastoma of the jaws .  An analysis of a consecutive series 
of all cases reported to the Swedish Cancer Registry during 1958 -1971."  Acta Pathol Microbiol 
Scand A .  86a(5) :337-349. 
Long GV, et al.  (2015).  “Dabrafenib and trametinib versus dabrafenib and placebo for Val600 
BRAF -mutant melanoma:  a multicentre, double -blind, phase  3 randomised controlled trial.”  
Lancet .  386(9992):444 -451. 
Lu Y, Xuan M, Takata T .  (1998) .  “Odontogenic tumors .  A demographic study of 759 cases in a 
Chinese population. ”  Oral Surg Oral Med Oral Pathol Oral Radiol Endod .  86(6) :707-714. 
Malassez L .  (1885) .  “Sur les role des débris épi[CONTACT_3433]éliaux paradentaires .”  Arch Physiol Norm 
Pathol .  5,6:309-340, 379 -449. 
Mosadomi, A .  (1975) .  “Odontogenic tumors in an African population .  Analysis of twenty -nine 
cases seen over a 5 -year period. ”  Oral Surg Oral Med Oral Pathol .  40(4) :502-521. 
Ndukwe  KC, Adebiyi EK, Ugboko VI,  et al.  (2010) .  “Ameloblastic carcinoma :  a multicenter 
Nigerian study. ”  J Oral Maxillofac Surg .  68(9) :2111 -2114 . 
Pandya NJ, Stuteville OH .  (1972) .  “Treatment of ameloblastoma .”  Plast Reconstr Surg .”  
50(3) :242-248. 
Ramadas K , Jose CC, Subhashini J,  et al.  (1990) .  “Pulmonary met astases from ameloblastoma of 
the mandible treated with cisplatin, adriamycin, and cyclophosphamide. ”  Cancer .  
66(7) :1475 -1479 . 
Regezi  JA, Kerr DA, Courtney RM (1978) .  “Odontogenic tumors :  analysis of 706 cases. ”  J Oral 
Surg .  36(10) :771-778. 
IRB-[ADDRESS_1105781]  2018;  Amendment  8 Reichart  PA, Philipsen HP, Sonner S .  (1995) .  “Ameloblastoma :  biological profile of 3677 
cases. ”  Eur J Cancer B Oral Oncol .  31b(2) :86-99. 
Robert C, et al.  (2015) .  “Improved overall survival in melanoma with combined dabrafenib and 
trametinib. ”  N Engl J Med .  372(1) :30-39. 
Schafer  DR, Thompson LD, Smith BC,  et al.  (1998) .  “Primary ameloblastoma of the sinonasal 
tract:  a clinicopathologic study of 24 cases. ”  Cancer .  82(4) :667-674. 
Sham E , Leong J, Maher R,  et al.  (2009) .  “Mandibular ameloblastoma :  clinic al experience and 
literature review. ”  ANZ J Surg .  79(10) :739-744. 
Slootweg  PJ, Muller H. (1984) .  “Malignant ameloblastoma or ameloblastic carcinoma. ”  Oral 
Surg Oral Med Oral Pathol .  57(2) :168-176. 
Stanley  HR, Diehl DL.  (1965) .  "Ameloblastoma Potenti al of Follicular Cysts ."  Oral Surg Oral 
Med Oral Pathol .  20:260-268. 
Sweeney  RT, McClary AC, Myers BR,  et al.  (2014) .  “Identification of recurrent SMO and BRAF 
mutations in ameloblastomas .”  Nat Genet .  46(7) :722-725. 
Tsai CY, Wei FC, Chang YL,  et al.  (2006) .  "Vastus lateralis muscle flap used for reconstruction 
of the maxilla after radical resection of recurrent ameloblastoma." Chang Gung Med J 
29(3) :331-335. 
Ueno S , Mushimoto K, Shirasu R al.  (1989) .  "Prognostic evaluation of ameloblastoma based on  
histologic and radiographic typi[INVESTIGATOR_007]." J Oral Maxillofac Surg 47(1) :11-15. 
Urken ML, et al.  (1991) .  “Functional evaluation following microvascular oromandibular 
reconstruction of the oral cancer patient :  a comparative study of reconstructed and 
nonrecons tructed patients. ”  Laryngoscope .  101(9) :935-950. 
Urken ML, Buchbinder D, Costantino PD, et al.  (1998).  “ Oromandibular reconstruction using 
microvascular composite flaps :  report of 210 cases. ”  Arch Otolaryngol Head Neck Surg .  
124:46 -55.  
Vayvada H , Mola F, Menderes A,  et al.  (2006) .  “Surgical management of ameloblastoma in the 
mandible :  Segmental mandibulectomy and immediate reconstruction with free fibula or deep 
circumflex iliac artery flap (evaluation of the long -term esthetic and functional res ults). ”  J Oral 
Maxillofac Surg . 64(10) :1532 -1539 .  
Wedl C .  (1870) .  Pathologie der Zähne :  mit besonderer Rücksicht auf Anatomie und Physiologie .  
Felix .   
Wenig  BM.  (2008) .  Atlas of head and neck pathology .  Elsevier Health Sciences .   
Williams, CB, et al.  (2015) .  “A metastatic colon adenocarcinoma harboring BRAF -V600E has a 
durable major response to dabrafenib/trametinib and chemotherapy. ”  Onco Targets .  Ther 
8:3561 -3564.  
Williams TP .  (1993) .  “Management of ameloblastoma :  a changing perspective. ”  J Oral 
Maxillofac Surg .  51(10) :1064 -1070 .  
Wu PC, Chan KW. (1985) .  “A survey of tumours of the jawbones in Hong Kong Chinese :  
1963 -1982. ”  Br J Oral Maxillofac Surg .  23(2) :92-102. 
Zwahlen  RA, Gratz KW. (2002) .  "Maxillary ameloblastomas :  a review o f the literature and of a 
15-year database."   J Craniomaxillofac Surg .  30(5) :273-279. 
IRB-[ADDRESS_1105782]  2018;  Amendment  8 Appendix  A:  Medication guide  / Patient Information  for patients : 
Dabrafenib capsules  
The current Medication Guide for Tafinlar  (dabrafenib) dated November  [ADDRESS_1105783]  (trametinib) is pr ovided in the package insert dated 
November  2015, attached to the eProtocol IRB -[ZIP_CODE] application.  
 
Appendix  B:  Stanford  Cance r Institute Standard Operating Procedures  
Standard Operating Procedures (SOPs) for the Stanford Cancer Institute  (SCI) pertaining to risks 
to subjects and safety reporting are available on the SCI Cancer Clinical Trials Office website 
(http://med.stanford.edu/ccto/services/regulatory.html ).  
 
IRB-[ADDRESS_1105784]  2018;  Amendment  8 Appendix  C:  ECOG performance status  
 
 
 
IRB-[ADDRESS_1105785]  2018;  Amendment  8 Appendix  D:  Cockcroft -Gault formula:  
CCr={((l 40 –age) x weight)/(72xSCr)}x 0.85 (if female)  
Appendix  E:  Ophthalmic exam source sheet  
Note to examiner :  Please assess particularly for visible retinal pathology.  
* Optical coherence tomography is highly recommended   For patients in whom retinal abnormalities are noted, 
color fundus photos, and fluorescein angiog raphy if clinically indicated, are recommended.   
OPHTHALMIC EXAMINATION  Subject name/ MRN:  
1. Date of Examination:  _ _/_ _ _ /_ _ _ _  
   dd  /   mmm   /    yyyy  
VISUAL ACUITY  
Enter corrected visual acuity  OD: OS: 
TONOMETRY  
Enter IOP (mmHg)  OD: OS: 
INDIRECT FUNDOSCOPY  
Indirect Exam: Indicate 
normal or specify abnormalities  OD: OS: 
CONFRONTATION VISUAL FIELD EXAM OR AUTOMATED PERIMETRY 
(eg, Humphrey 24 -2 or 30 -2 or equivalent if using a non -Humphrey instrument)  
Indicate normal or specify any 
abnorm alities  OD: OS: 
OPTICAL COHERENCE TOMOGRAPHY (strongly recommended)  
Indicate normal or specify any 
abnormalities  OD: OS: 
COLOR FUNDUS PHOTOS (recommended if retinal abnormalities are noted)*  
Indicate normal or specify any 
abnormalities  OD: OS: 
FLORESC EIN ANGIOGRAPHY (suggested if retinal abnormalities are noted and 
test clinically indicated)*  
Indicate normal or specify any 
abnormalities  OD: OS: 
Were any of the following noted on ocular history or exam?  Yes No 
 History of CSR?    
 Evidence of new optic  disc cuppi[INVESTIGATOR_007]?    
 Evidence of new visual field defects?    
EXCLUSION CRITERIA  Yes No 
 History of RVO?  
o If yes, patient is not eligible for the study.    
Signature [CONTACT_498388]: _____________________________   
Printed Name: _________________________      Date : ______________  